{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:11:14Z","timestamp":1791159074159,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,7,24]],"date-time":"2014-07-24T00:00:00Z","timestamp":1406160000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/s13023-014-0112-x","type":"journal-article","created":{"date-parts":[[2014,7,23]],"date-time":"2014-07-23T08:28:19Z","timestamp":1406104099000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Modelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications"],"prefix":"10.1186","volume":"9","author":[{"given":"Laura","family":"van Dussen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Biegstraaten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel GW","family":"Dijkgraaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla EM","family":"Hollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,7,24]]},"reference":[{"key":"112_CR1","volume-title":"The Online Metabolic & Molecular Bases of Inherited Disease","author":"GA Grabowski","year":"2010","unstructured":"Grabowski GA, Petsko GA, Kolodny EH: Gaucher Disease. The Online Metabolic & Molecular Bases of Inherited Disease. Edited by: Valle D, Beaudet AL, Vogelstein B, Kinzler K, Antonarakis SE, Ballabio A. New York: McGraw-Hill, 2010."},{"key":"112_CR2","first-page":"33","volume":"95","author":"EH Kolodny","year":"1982","unstructured":"Kolodny EH, Ullman MD, Mankin HJ, Raghavan SS, Topol J, Sullivan JL: Phenotypic manifestations of Gaucher disease: clinical features in 48 biochemically verified type 1 patients and comment on type 2 patients. ProgClinBiolRes. 1982, 95: 33-65.","journal-title":"ProgClinBiolRes"},{"key":"112_CR3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.bcmd.2005.08.004","volume":"36","author":"M de Fost","year":"2006","unstructured":"de Fost M, vom Dahl S, Weverling GJ, Brill N, Brett S, Haussinger D, Hollak CE: Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis. 2006, 36: 53-58. 10.1016\/j.bcmd.2005.08.004.","journal-title":"Blood Cells Mol Dis"},{"key":"112_CR4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/1097-0142(19930701)72:1<219::AID-CNCR2820720139>3.0.CO;2-Y","volume":"72","author":"A Shiran","year":"1993","unstructured":"Shiran A, Brenner B, Laor A, Tatarsky I: Increased risk of cancer in patients with Gaucher disease. Cancer. 1993, 72: 219-224. 10.1002\/1097-0142(19930701)72:1<219::AID-CNCR2820720139>3.0.CO;2-Y.","journal-title":"Cancer"},{"key":"112_CR5","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/qjmed\/89.9.691","volume":"89","author":"O Neudorfer","year":"1996","unstructured":"Neudorfer O, Giladi N, Elstein D, Abrahamov A, Turezkite T, Aghai E, Reches A, Bembi B, Zimran A: Occurrence of Parkinson\u2019s syndrome in type I Gaucher disease. QJM. 1996, 89: 691-694. 10.1093\/qjmed\/89.9.691.","journal-title":"QJM"},{"key":"112_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/S1096-7192(03)00071-4","volume":"79","author":"N Tayebi","year":"2003","unstructured":"Tayebi N, Walker J, Stubblefield B, Orvisky E, LaMarca ME, Wong K, Rosenbaum H, Schiffmann R, Bembi B, Sidransky E: Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?. Mol Genet Metab. 2003, 79: 104-109. 10.1016\/S1096-7192(03)00071-4.","journal-title":"Mol Genet Metab"},{"key":"112_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1096-7192(02)00122-1","volume":"77","author":"PK Mistry","year":"2002","unstructured":"Mistry PK, Sirrs S, Chan A, Pritzker MR, Duffy TP, Grace ME, Meeker DP, Goldman ME: Pulmonary hypertension in type 1 Gaucher\u2019s disease: genetic and epigenetic determinants of phenotype and response to therapy. Mol Genet Metab. 2002, 77: 91-98. 10.1016\/S1096-7192(02)00122-1.","journal-title":"Mol Genet Metab"},{"key":"112_CR8","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1161\/01.CIR.35.4.783","volume":"35","author":"WC Roberts","year":"1967","unstructured":"Roberts WC, Fredrickson DS: Gaucher\u2019s disease of the lung causing severe pulmonary hypertension with associated acute recurrent pericarditis. Circulation. 1967, 35: 783-789. 10.1161\/01.CIR.35.4.783.","journal-title":"Circulation"},{"key":"112_CR9","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1111\/bjh.12335","volume":"161","author":"M Arends","year":"2013","unstructured":"Arends M, van Dussen L, Biegstraaten M, Hollak CE: Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature. Br J Haematol. 2013, 161: 832-842. 10.1111\/bjh.12335.","journal-title":"Br J Haematol"},{"key":"112_CR10","doi-asserted-by":"publisher","first-page":"e57507","DOI":"10.1371\/journal.pone.0057507","volume":"8","author":"AE Bohte","year":"2013","unstructured":"Bohte AE, van Dussen L, Akkerman EM, Nederveen AJ, Sinkus R, Jansen PL, Stoker J, Hollak CE: Liver fibrosis in type I Gaucher disease: magnetic resonance imaging, transient elastography and parameters of iron storage. PLoS One. 2013, 8: e57507-10.1371\/journal.pone.0057507.","journal-title":"PLoS One"},{"key":"112_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/0002-9610(91)90363-I","volume":"161","author":"PR Fleshner","year":"1991","unstructured":"Fleshner PR, Aufses AH, Grabowski GA, Elias R: A 27-year experience with splenectomy for Gaucher\u2019s disease. Am J Surg. 1991, 161: 69-75. 10.1016\/0002-9610(91)90363-I.","journal-title":"Am J Surg"},{"key":"112_CR12","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/ajh.21684","volume":"85","author":"SM Lo","year":"2010","unstructured":"Lo SM, Stein P, Mullaly S, Bar M, Jain D, Pastores GM, Mistry PK: Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types\u2013correlation with genotype and phenotype. Am J Hematol. 2010, 85: 340-345.","journal-title":"Am J Hematol"},{"key":"112_CR13","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1182\/blood-2010-06-293902","volume":"116","author":"E Lukina","year":"2010","unstructured":"Lukina E, Watman N, Arreguin EA, Dragosky M, Iastrebner M, Rosenbaum H, Phillips M, Pastores GM, Kamath RS, Rosenthal DI, Kaper M, Singh T, Puga AC, Peterschmitt MJ: Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood. 2010, 116: 4095-4098. 10.1182\/blood-2010-06-293902.","journal-title":"Blood"},{"key":"112_CR14","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ymgme.2007.04.001","volume":"91","author":"KA McEachern","year":"2007","unstructured":"McEachern KA, Fung J, Komarnitsky S, Siegel CS, Chuang WL, Hutto E, Shayman JA, Grabowski GA, Aerts JM, Cheng SH, Copeland DP, Marshall J: A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab. 2007, 91: 259-267. 10.1016\/j.ymgme.2007.04.001.","journal-title":"Mol Genet Metab"},{"key":"112_CR15","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","volume":"324","author":"NW Barton","year":"1991","unstructured":"Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, Mankin HJ, Murray GJ, Parker RI, Argoff CE: Replacement therapy for inherited enzyme deficiency\u2013macrophage-targeted glucocerebrosidase for Gaucher\u2019s disease. N Engl J Med. 1991, 324: 1464-1470. 10.1056\/NEJM199105233242104.","journal-title":"N Engl J Med"},{"key":"112_CR16","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1073\/pnas.87.5.1913","volume":"87","author":"NW Barton","year":"1990","unstructured":"Barton NW, Furbish FS, Murray GJ, Garfield M, Brady RO: Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci U S A. 1990, 87: 1913-1916. 10.1073\/pnas.87.5.1913.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"112_CR17","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood.V78.5.1183.1183","volume":"78","author":"E Beutler","year":"1991","unstructured":"Beutler E, Kay A, Saven A, Garver P, Thurston D, Dawson A, Rosenbloom B: Enzyme replacement therapy for Gaucher disease. Blood. 1991, 78: 1183-1189.","journal-title":"Blood"},{"key":"112_CR18","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJM199212033272304","volume":"327","author":"ML Figueroa","year":"1992","unstructured":"Figueroa ML, Rosenbloom BE, Kay AC, Garver P, Thurston DW, Koziol JA, Gelbart T, Beutler E: A less costly regimen of alglucerase to treat Gaucher\u2019s disease. N Engl J Med. 1992, 327: 1632-1636. 10.1056\/NEJM199212033272304.","journal-title":"N Engl J Med"},{"key":"112_CR19","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/S0140-6736(95)91037-9","volume":"345","author":"CE Hollak","year":"1995","unstructured":"Hollak CE, Aerts JM, Goudsmit R, Phoa SS, Ek M, van Weely S, von dem Borne AE, van Oers MH: Individualised low-dose alglucerase therapy for type 1 Gaucher\u2019s disease. Lancet. 1995, 345: 1474-1478. 10.1016\/S0140-6736(95)91037-9.","journal-title":"Lancet"},{"key":"112_CR20","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1182\/blood.V82.2.408.408","volume":"82","author":"GM Pastores","year":"1993","unstructured":"Pastores GM, Sibille AR, Grabowski GA: Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24\u00a0months. Blood. 1993, 82: 408-416.","journal-title":"Blood"},{"key":"112_CR21","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/00005792-199211000-00002","volume":"71","author":"A Zimran","year":"1992","unstructured":"Zimran A, Kay A, Gelbart T, Garver P, Thurston D, Saven A, Beutler E: Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine (Baltimore). 1992, 71: 337-353. 10.1097\/00005792-199211000-00002.","journal-title":"Medicine (Baltimore)"},{"key":"112_CR22","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.3324\/haematol.12651","volume":"93","author":"M de Fost","year":"2008","unstructured":"de Fost M, van Noesel CJ, Aerts JM, Maas M, Poll RG, Hollak CE: Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy. Haematologica. 2008, 93: 1119-1120. 10.3324\/haematol.12651.","journal-title":"Haematologica"},{"key":"112_CR23","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1023\/A:1008814105603","volume":"7","author":"AM Damiano","year":"1998","unstructured":"Damiano AM, Pastores GM, Ware JE: The health-related quality of life of adults with Gaucher\u2019s disease receiving enzyme replacement therapy: results from a retrospective study. Qual Life Res. 1998, 7: 373-386. 10.1023\/A:1008814105603.","journal-title":"Qual Life Res"},{"key":"112_CR24","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s11136-004-0794-y","volume":"14","author":"P Giraldo","year":"2005","unstructured":"Giraldo P, Solano V, Perez-Calvo JI, Giralt M, Rubio-Felix D: Quality of life related to type 1 Gaucher disease: Spanish experience. Qual Life Res. 2005, 14: 453-462. 10.1007\/s11136-004-0794-y.","journal-title":"Qual Life Res"},{"key":"112_CR25","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1023\/A:1008878425167","volume":"7","author":"RP Hayes","year":"1998","unstructured":"Hayes RP, Grinzaid KA, Duffey EB, Elsas LJ: The impact of Gaucher disease and its treatment on quality of life. Qual Life Res. 1998, 7: 521-534. 10.1023\/A:1008878425167.","journal-title":"Qual Life Res"},{"key":"112_CR26","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1023\/A:1008859420641","volume":"8","author":"BJ Masek","year":"1999","unstructured":"Masek BJ, Sims KB, Bove CM, Korson MS, Short P, Norman DK: Quality of life assessment in adults with type 1 Gaucher disease. Qual Life Res. 1999, 8: 263-268. 10.1023\/A:1008859420641.","journal-title":"Qual Life Res"},{"key":"112_CR27","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/j.1399-0004.2007.00811.x","volume":"71","author":"N Weinreb","year":"2007","unstructured":"Weinreb N, Barranger J, Packman S, Prakash-Cheng A, Rosenbloom B, Sims K, Angell J, Skrinar A, Pastores GM: Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease. Clin Genet. 2007, 71: 576-588. 10.1111\/j.1399-0004.2007.00811.x.","journal-title":"Clin Genet"},{"key":"112_CR28","first-page":"iii","volume":"10","author":"M Connock","year":"2006","unstructured":"Connock M, Burls A, Frew E, Fry-Smith A, Juarez-Garcia A, McCabe C, Wailoo A, Abrams K, Cooper N, Sutton A, O\u2019Hagan A, Moore D: The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher\u2019s disease: a systematic review. Health Technol Assess. 2006, 10: iii-136.","journal-title":"Health Technol Assess"},{"key":"112_CR29","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ajh.21362","volume":"84","author":"TH Taddei","year":"2009","unstructured":"Taddei TH, Kacena KA, Yang M, Yang R, Malhotra A, Boxer M, Aleck KA, Rennert G, Pastores GM, Mistry PK: The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol. 2009, 84: 208-214. 10.1002\/ajh.21362.","journal-title":"Am J Hematol"},{"key":"112_CR30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1750-1172-9-51","volume":"9","author":"L van Dussen","year":"2014","unstructured":"van Dussen L, Biegstraaten M, Hollak CE, Dijkgraaf MG: Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease. Orphanet J Rare Dis. 2014, 9: 51-10.1186\/1750-1172-9-51.","journal-title":"Orphanet J Rare Dis"},{"key":"112_CR31","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","volume":"117","author":"C Neunert","year":"2011","unstructured":"Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA: The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011, 117: 4190-4207. 10.1182\/blood-2010-08-302984.","journal-title":"Blood"},{"key":"112_CR32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","volume":"41","author":"GM Pastores","year":"2004","unstructured":"Pastores GM, Weinreb NJ, Aerts H, Andria G, Cox TM, Giralt M, Grabowski GA, Mistry PK, Tylki-Szymanska A: Therapeutic goals in the treatment of Gaucher disease. Semin Hematol. 2004, 41: 4-14. 10.1053\/j.seminhematol.2004.07.009.","journal-title":"Semin Hematol"},{"key":"112_CR33","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/j.1445-2197.2007.04405.x","volume":"78","author":"J Ludbrook","year":"2008","unstructured":"Ludbrook J, Royse AG: Analysing clinical studies: principles, practice and pitfalls of Kaplan-Meier plots. ANZ J Surg. 2008, 78: 204-210. 10.1111\/j.1445-2197.2007.04405.x.","journal-title":"ANZ J Surg"},{"key":"112_CR34","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.bcmd.2009.12.006","volume":"44","author":"JM Boomsma","year":"2010","unstructured":"Boomsma JM, van Dussen L, Wiersma MG, Groener JE, Aerts JM, Maas M, Hollak CE: Spontaneous regression of disease manifestations can occur in type 1 Gaucher disease; results of a retrospective cohort study. Blood Cells Mol Dis. 2010, 44: 181-187. 10.1016\/j.bcmd.2009.12.006.","journal-title":"Blood Cells Mol Dis"},{"key":"112_CR35","first-page":"3085","volume":"91","author":"D Krasnewich","year":"1998","unstructured":"Krasnewich D, Dietrich K, Bauer L, Ginns EI, Sidransky E, Hill S: Splenectomy in Gaucher disease: new management dilemmas. Blood. 1998, 91: 3085-3087.","journal-title":"Blood"},{"key":"112_CR36","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood.V90.1.43.43_43_48","volume":"90","author":"E Ponce","year":"1997","unstructured":"Ponce E, Moskovitz J, Grabowski G: Enzyme therapy in Gaucher disease type 1: effect of neutralizing antibodies to acid beta-glucosidase. Blood. 1997, 90: 43-48.","journal-title":"Blood"},{"key":"112_CR37","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1542\/peds.96.4.629","volume":"96","author":"DI Rosenthal","year":"1995","unstructured":"Rosenthal DI, Doppelt SH, Mankin HJ, Dambrosia JM, Xavier RJ, McKusick KA, Rosen BR, Baker J, Niklason LT, Hill SC: Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics. 1995, 96: 629-637.","journal-title":"Pediatrics"},{"key":"112_CR38","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1006\/bcmd.2001.0474","volume":"27","author":"C Hollak","year":"2001","unstructured":"Hollak C, Maas M, Akkerman E, den Heeten A, Aerts H: Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease. Blood Cells Mol Dis. 2001, 27: 1005-1012. 10.1006\/bcmd.2001.0474.","journal-title":"Blood Cells Mol Dis"},{"key":"112_CR39","doi-asserted-by":"publisher","first-page":"961","DOI":"10.2214\/ajr.179.4.1790961","volume":"179","author":"M Maas","year":"2002","unstructured":"Maas M, Hollak CE, Akkerman EM, Aerts JM, Stoker J, den Heeten GJ: Quantification of skeletal involvement in adults with type I Gaucher\u2019s disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter. AJR Am J Roentgenol. 2002, 179: 961-965. 10.2214\/ajr.179.4.1790961.","journal-title":"AJR Am J Roentgenol"},{"key":"112_CR40","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s002560100375","volume":"30","author":"LW Poll","year":"2001","unstructured":"Poll LW, Koch JA, vom Dahl S, Willers R, Scherer A, Boerner D, Niederau C, Haussinger D, Modder U: Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results. Skeletal Radiol. 2001, 30: 496-503. 10.1007\/s002560100375.","journal-title":"Skeletal Radiol"},{"key":"112_CR41","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1148\/radiol.2292020296","volume":"229","author":"M Maas","year":"2003","unstructured":"Maas M, van Kuijk C, Stoker J, Hollak CE, Akkerman EM, Aerts JF, den Heeten GJ: Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging\u2013initial experience. Radiology. 2003, 229: 554-561. 10.1148\/radiol.2292020296.","journal-title":"Radiology"},{"issue":"Suppl 1","key":"112_CR42","doi-asserted-by":"publisher","first-page":"A37","DOI":"10.1259\/bjr.75.suppl_1.750037","volume":"75","author":"B Bembi","year":"2002","unstructured":"Bembi B, Ciana G, Mengel E, Terk MR, Martini C, Wenstrup RJ: Bone complications in children with Gaucher disease. Br J Radiol. 2002, 75 (Suppl 1): A37-A44. 10.1259\/bjr.75.suppl_1.750037.","journal-title":"Br J Radiol"},{"key":"112_CR43","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s10545-005-0032-y","volume":"28","author":"G Ciana","year":"2005","unstructured":"Ciana G, Addobbati R, Tamaro G, Leopaldi A, Nevyjel M, Ronfani L, Vidoni L, Pittis MG, Bembi B: Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy. J Inherit Metab Dis. 2005, 28: 723-732. 10.1007\/s10545-005-0032-y.","journal-title":"J Inherit Metab Dis"},{"key":"112_CR44","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1006\/bcmd.2002.0517","volume":"28","author":"R Schiffmann","year":"2002","unstructured":"Schiffmann R, Mankin H, Dambrosia JM, Xavier RJ, Kreps C, Hill SC, Barton NW, Rosenthal DI: Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy. Blood Cells Mol Dis. 2002, 28: 288-296. 10.1006\/bcmd.2002.0517.","journal-title":"Blood Cells Mol Dis"},{"key":"112_CR45","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/j.1399-0004.2008.00978.x","volume":"73","author":"KB Sims","year":"2008","unstructured":"Sims KB, Pastores GM, Weinreb NJ, Barranger J, Rosenbloom BE, Packman S, Kaplan P, Mankin H, Xavier R, Angell J, Fitzpatrick MA, Rosenthal D: Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. Clin Genet. 2008, 73: 430-440. 10.1111\/j.1399-0004.2008.00978.x.","journal-title":"Clin Genet"},{"key":"112_CR46","doi-asserted-by":"publisher","first-page":"182","DOI":"10.2217\/ebo.13.241","volume-title":"Advances in Gaucher Disease: Basic and Clinical Perspectives. Future Medicine Ltd","author":"L van Dussen","year":"2013","unstructured":"van Dussen L, Maas M, Hangartner TN: Imaging Skeletal Involvement in Gaucher Disease. In Advances in Gaucher Disease: Basic and Clinical Perspectives. Future Medicine Ltd; 2013:182\u2013200."},{"key":"112_CR47","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1182\/blood-2006-07-033233","volume":"109","author":"CE Hollak","year":"2007","unstructured":"Hollak CE, de Fost M, Aerts JM, vom Dahl S: Low-dose versus high-dose therapy for gaucher disease: goals and markers. Blood. 2007, 109: 387-388. 10.1182\/blood-2006-07-033233.","journal-title":"Blood"},{"key":"112_CR48","first-page":"33","volume":"32","author":"N Belmatoug","year":"1995","unstructured":"Belmatoug N, de Villemeur TB: Skeletal response to enzyme replacement therapy for type I gaucher disease: a preliminary report of the french experience. Semin Hematol. 1995, 32: 33-38.","journal-title":"Semin Hematol"},{"key":"112_CR49","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/MD.0b013e3182057be4","volume":"90","author":"PB Deegan","year":"2011","unstructured":"Deegan PB, Pavlova E, Tindall J, Stein PE, Bearcroft P, Mehta A, Hughes D, Wraith JE, Cox TM: Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy. Medicine (Baltimore). 2011, 90: 52-60. 10.1097\/MD.0b013e3182057be4.","journal-title":"Medicine (Baltimore)"},{"key":"112_CR50","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s10545-006-0121-6","volume":"29","author":"A El-Beshlawy","year":"2006","unstructured":"El-Beshlawy A, Ragab L, Youssry I, Yakout K, El-Kiki H, Eid K, Mansour IM, Abd El-Hamid S, Yang M, Mistry PK: Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients. J Inherit Metab Dis. 2006, 29: 92-98. 10.1007\/s10545-006-0121-6.","journal-title":"J Inherit Metab Dis"},{"key":"112_CR51","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1006\/bcmd.1996.0016","volume":"22","author":"D Elstein","year":"1996","unstructured":"Elstein D, Hadas-Halpern I, Itzchaki M, Lahad A, Abrahamov A, Zimran A: Effect of low-dose enzyme replacement therapy on bones in Gaucher disease patients with severe skeletal involvement. Blood Cells Mol Dis. 1996, 22: 104-111. 10.1006\/bcmd.1996.0016.","journal-title":"Blood Cells Mol Dis"},{"key":"112_CR52","doi-asserted-by":"publisher","first-page":"R156","DOI":"10.1186\/ar3111","volume":"12","author":"J Stirnemann","year":"2010","unstructured":"Stirnemann J, Belmatoug N, Vincent C, Fain O, Fantin B, Mentre F: Bone events and evolution of biologic markers in Gaucher disease before and during treatment. Arthritis Res Ther. 2010, 12: R156-10.1186\/ar3111.","journal-title":"Arthritis Res Ther"},{"key":"112_CR53","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1399-0004.2007.00769.x","volume":"71","author":"J Charrow","year":"2007","unstructured":"Charrow J, Dulisse B, Grabowski GA, Weinreb NJ: The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin Genet. 2007, 71: 205-211. 10.1111\/j.1399-0004.2007.00769.x.","journal-title":"Clin Genet"},{"key":"112_CR54","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","volume":"113","author":"NJ Weinreb","year":"2002","unstructured":"Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Rosenbloom BE, Scott CR, Wappner RS, Zimran A: Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5\u00a0years of treatment: a report from the Gaucher Registry. Am J Med. 2002, 113: 112-119. 10.1016\/S0002-9343(02)01150-6.","journal-title":"Am J Med"},{"key":"112_CR55","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1365-2141.2009.07872.x","volume":"147","author":"PK Mistry","year":"2009","unstructured":"Mistry PK, Deegan P, Vellodi A, Cole JA, Yeh M, Weinreb NJ: Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis. Br J Haematol. 2009, 147: 561-570. 10.1111\/j.1365-2141.2009.07872.x.","journal-title":"Br J Haematol"},{"key":"112_CR56","first-page":"177","volume":"95","author":"RE Lee","year":"1982","unstructured":"Lee RE: The pathology of Gaucher disease. Prog Clin Biol Res. 1982, 95: 177-217.","journal-title":"Prog Clin Biol Res"},{"key":"112_CR57","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1056\/NEJMoa01133202","volume":"346","author":"RA Kyle","year":"2002","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton LJ: A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002, 346: 564-569. 10.1056\/NEJMoa01133202.","journal-title":"N Engl J Med"},{"key":"112_CR58","first-page":"1108","volume":"121","author":"K Brady","year":"1997","unstructured":"Brady K, Corash L, Bhargava V: Multiple myeloma arising from monoclonal gammopathy of undetermined significance in a patient with Gaucher\u2019s disease. Arch Pathol Lab Med. 1997, 121: 1108-1111.","journal-title":"Arch Pathol Lab Med"},{"key":"112_CR59","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1615\/CritRevOncog.2013005921","volume":"18","author":"NJ Weinreb","year":"2013","unstructured":"Weinreb NJ, Lee RE: Causes of death due to hematological and non-hematological cancers in 57 US patients with type 1 Gaucher Disease who were never treated with enzyme replacement therapy. Crit Rev Oncog. 2013, 18: 177-195. 10.1615\/CritRevOncog.2013005921.","journal-title":"Crit Rev Oncog"},{"key":"112_CR60","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1182\/blood-2005-12-5072","volume":"108","author":"M de Fost","year":"2006","unstructured":"de Fost M, Hollak CE, Groener JE, Aerts JM, Maas M, Poll LW, Wiersma MG, Haussinger D, Brett S, Brill N, vom Dahl S: Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis. Blood. 2006, 108: 830-835. 10.1182\/blood-2005-12-5072.","journal-title":"Blood"},{"key":"112_CR61","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/GIM.0b013e31818e2c19","volume":"11","author":"GA Grabowski","year":"2009","unstructured":"Grabowski GA, Kacena K, Cole JA, Hollak CE, Zhang L, Yee J, Mistry PK, Zimran A, Charrow J, vom Dahl S: Dose\u2013response relationships for enzyme replacement therapy with imiglucerase\/alglucerase in patients with Gaucher disease type 1. Genet Med. 2009, 11: 92-100. 10.1097\/GIM.0b013e31818e2c19.","journal-title":"Genet Med"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-014-0112-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-014-0112-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-014-0112-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-014-0112-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T02:05:38Z","timestamp":1717121138000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-014-0112-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,24]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["112"],"URL":"https:\/\/doi.org\/10.1186\/s13023-014-0112-x","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,24]]},"assertion":[{"value":"2 November 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"112"}}